ANVISA guidelines for two-stage design [Two-Stage / GS Designs]

posted by ElMaestro  – Denmark, 2020-02-12 08:27 (585 d 18:10 ago) – Posting: # 21162
Views: 4,381

Hi MS,

» Art.75. For two-stage studies, the following should be noted: It is acceptable to use a two-stage approach to demonstrate bioequivalence based on ignorance of the intra-individual variability of the drug;


Ermmm...... WHAT???? :-D:party:

Pass or fail!
ElMaestro

Complete thread:

Activity
 Admin contact
21,691 posts in 4,534 threads, 1,541 registered users;
online 3 (0 registered, 3 guests [including 2 identified bots]).
Forum time: Monday 03:38 CEST (Europe/Vienna)

They were “so intent of making everything numerical”
that they frequently missed seeing
what was there to be seen.    Barbara McClintock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5